

December 23<sup>rd</sup>, 2013

VRL/SEC/BSE/91

**Dept. of Corporate Services**  
**The Stock Exchange, Mumbai**  
**25<sup>th</sup> Floor, Phiroze Jeejeebhoy Towers**  
**Dalal Street, Mumbai**

**Sub. : Venus wins Innovative 100 Award for ELORES**

Dear Sir/Madam,


This is to inform you that Venus Remedies Limited has received Innovative 100 Award for its novel research product "ELORES", a drug designed to fight 'superbugs' to which other antibiotics failed to respond to, at an award function organized by "Inc India", business magazine in Delhi.

This award is a recognition for Venus' effort in the field of AMR. Elores is a new product and in a very short span of time, it has done exceptionally good in the market. Getting this award for Elores is the recognition of the company's years of research and efforts put in by its team to bring this product to the market.

Elores, the flagship product of Venus Remedies, is known for its efficacy against serious multidrug-resistant hospital-acquired infections involving metallo-beta-lactamase and carbapenem-resistant strains of bacteria such as *E. coli*, *K. pneumoniae*, *P. aeruginosa* and *A. baumannii*. Infections caused by resistant microorganisms are failing to respond to conventional treatment, thereby resulting in prolonged illness and greater risk of death. Elores has a unique profile of action, which gives it an edge over all the existing therapies.

Globally the systemic antibacterial market is set to reach approx US \$44 billion by 2016 and is growing with a CAGR of 7.2%. Elores is capable of addressing Multidrug resistant ESBL/MBL producing gram negative infections which constitute 25% of this market creating an opportunity of more than US \$11 billion in coming 5 to 6 years. Elores has patent for product, method of treatment and use protected from 45 countries including USA, India, Australia and Europe. Elores was launched in Indian market in early this year and has received tremendous response from medical fraternity.

Yours faithfully,  
for VENUS REMEDIES LIMITED.



Ramanjit Kaur  
Deputy Manager  
Corporate Communication

**VENUS REMEDIES LIMITED**

Corporate Office :  
Industrial Area, Phase- I,  
Panchkula (Hry.) 134113, India  
Regional Office :  
Cabin No. 10, 2nd Floor, NAC,  
Chandigarh (U.T.) 160101, India  
Website : [www.venusremedies.com](http://www.venusremedies.com)  
[www.venusmedicineresearchcentre.com](http://www.venusmedicineresearchcentre.com)



Unit-I :  
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India  
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565577  
Unit-II :  
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),  
Bhatoli Kalan, Baddi (H.P.) 173205, India  
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272  
Unit-V :  
VENUS PHARMA GmbH  
AM Bahnhof 1-3, D-59368, Werne, Germany